Lamivudine Teva

Lamivudine, the active ingredient in Lamivudine Teva, is a nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It treats HIV infection and chronic hepatitis B in adults and children as prescribed.

GNH USA supplies Lamivudine Teva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine is used in antiretroviral therapy and antiviral treatment of hepatitis B, targeting viral replication pathways.

- HIV infection: reduces viral load and slows disease progression when used in combination antiretroviral regimens. - Chronic hepatitis B: suppresses HBV DNA replication and improves liver function in infected patients. - Prevention of mother‑to‑child HIV transmission: lowers the risk of vertical transmission when administered to pregnant women as part of combination therapy.

Lamivudine may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Nausea - Headache - Fatigue - Diarrhea - Abdominal pain - Insomnia

Serious or Rare Side Effects: - Lactic acidosis - Severe hepatotoxicity - Pancreatitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Bone marrow suppression - Hypersensitivity reactions (e.g., rash, fever).

When prescribing Lamivudine, clinicians should consider several safety and handling precautions. - Renal function: adjust dose in patients with severe renal impairment. - Hepatic disease: monitor liver enzymes regularly. - Pregnancy: evaluate risk‑benefit before use. - Concomitant medications: review for potential interactions. - Adherence: emphasize importance of consistent dosing to prevent resistance. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Lamivudine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis. - Stavudine: heightened mitochondrial toxicity. - Zidovudine: additive bone marrow suppression. - Co‑administration with other NRTIs causing overlapping toxicity. - Nephrotoxic agents: may worsen renal function.

Moderate Interactions (Monitor Closely): - Protease inhibitors (e.g., ritonavir): may increase lamivudine levels. - Non‑nucleoside reverse transcriptase inhibitors (e.g., efavirenz): may affect plasma concentrations. - Antacids containing aluminum or magnesium: may reduce absorption. - Warfarin: monitor INR as lamivudine may alter anticoagulant effect. - Live vaccines: may have reduced efficacy.